Zoek in het archief
 
terug

Check the original
News breaking: 2017-11-29

Maina Bhaman wordt partner bij Sofinnova Partners

PARIJS – (BUSINESS WIRE) – Sofinnova Partners, een leidende Life Sciences-venture capital-onderneming gericht op Europa, heeft Maina Bhaman aangesteld als partner.

Maina Bhaman komt naar Sofinnova Partners met een lange staat van dienst als succesvolle investeerder in de gezondheidszorg. Voordat zij toetrad, was zij vanaf 2006 directeur van Healthcare Investment bij Touchstone Innovations (voorheen Imperial Innovations) in Londen (VK). Zij heeft vele investeringen beheerd of medebeheerd en zat in de raad van bestuur van een aantal Britse biotechbedrijven, zoals Autifony, Cellmedica, Psioxus Therapeutics, Pulmocide, Topivert Pharma, Puridify (verkocht aan GE), Thiakis (verkocht aan Wyeth) en Respivert (verkocht aan J & J). Eerder werkte ze in de R & D-teams van verschillende Britse en Amerikaanse biotech-bedrijven, waaronder Celltech, Oxford Glyco Sciences, Chimeric Therapies en GeneMedicine. Maina heeft een BSc van de University of Texas in Austin (Verenigde Staten) en een MBA van de Imperial Business School in Londen (Verenigd Koninkrijk).

Maina Bhaman Joins Sofinnova Partners as Partner

PARIS–(BUSINESS WIRE)– Sofinnova Partners, a leading Life Sciences venture capital firm focused on Europe, has appointed Maina Bhaman as Partner.

Maina Bhaman comes to Sofinnova Partners with a long track record as a successful healthcare investor. Prior to joining, she was Director of Healthcare Investment at Touchstone Innovations (formerly Imperial Innovations) in London (UK) since 2006. She has led or co-led numerous investments and sat on the Board of a number of UK biotech companies, such as Autifony, Cellmedica, Psioxus Therapeutics, Pulmocide, Topivert Pharma, Puridify (sold to GE), Thiakis (sold to Wyeth) and Respivert (sold to J&J). Previously, she worked in the R&D teams of several UK and US biotech companies, including Celltech, Oxford Glyco Sciences, Chimeric Therapies and GeneMedicine. Maina has a BSc from the University of Texas at Austin (United States) and an MBA from the Imperial Business School in London (United Kingdom).

As a long standing member of the biotech ecosystem, Maina has received strong professional and institutional recognition; and was named one of UK’s Top women in Biopharma several years in a row. With Maina Bhaman’s arrival, Sofinnova Partners continues to build a truly international team with a unique diversity.

Maina Bhaman says: “I am thrilled to join such an experienced team as Sofinnova Partners. We have worked together on a number of co-investments, and clearly share a common approach and vision. I am looking forward to continue to pursue my passion of backing entrepreneurs developing paradigm-shifting technologies that may significantly improve patients’ life”.

Antoine Papiernik, Managing Partner and Chairman of Sofinnova Partners, adds: “We are extremely happy to welcome Maina as a Partner in our team. Her expertise and track record are a perfect match with our team and strategy. This recruitment also furthers our international reach and will positively contribute to Sofinnova Partners’ growth”.

 

 

View source version on businesswire.com: http://www.businesswire.com/news/home/20171128005894/en/

Contacts

Media

SOFINNOVA PARTNERS

Anne REIN, Tel: +33 6 03 35 92 05

@: anne.rein@strategiesimage.com

www.sofinnova.fr

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.